PHILADELPHIA – The Perelman School of Medicine at the University of Pennsylvania
is establishing the Asperger Syndrome Program of Excellence
(ASPE) with a $5.4 million gift from an anonymous donor. ASPE aims to significantly improve understanding of the genetic causes of Asperger syndrome in order to energize the international research and clinical community.
Asperger syndrome (AS) is defined as autism spectrum disorder (ASD) without intellectual disability. ASPE will be a central resource for individuals and families affected by AS and for clinicians and researchers seeking to partner with the program. It will also provide funds for research by new faculty, postdoctoral fellows, and graduate students. ASPE will take a two-pronged approach by conducting a pioneering family-based genetic study and simultaneously developing model systems to investigate specific mutations in genes found in earlier genome-wide association studies associated with AS and ASD.
“Penn is poised to make genetic discoveries that will significantly improve how the medical community approaches Asperger syndrome,” said Daniel J. Rader, MD, chair of Genetics and ASPE director. “ASPE will draw on our strength in genetics and psychiatry to push the field ahead to create new options for individuals and families. We are fortunate to be partnering with a truly forward-thinking philanthropist.”
Penn will host an international symposium for ASPE in the spring of 2018 to review early findings and stimulate new research avenues. World-renowned developmental psychologist Simon Baron-Cohen, director of the Autism Research Centre at University of Cambridge, will chair ASPE’s external advisory board. “ASPE’s work will be highly collaborative in nature, pulling together expertise from across the globe,” Rader said. “We are delighted to be partnering with Dr. Baron-Cohen and his colleagues from the outset.”
A major focus of ASPE will be on the NRXN1 gene, which codes for the protein neurexin 1 and has been associated with ASD and other psychiatric and neurodevelopmental disorders. The ASPE team will compare the genomes of individuals with and without mutations in the NRXN1 gene and individuals with AS and their family members who may or may not have been diagnosed with AS.
“Leveraging advanced technologies in genomic medicine and improved methods of behavioral assessment, we aim to identify genes that contribute to Asperger syndrome, to unveil how these genes function biologically, and to use this information to improve how we diagnose and treat Asperger syndrome,” said Maja Bucan, PhD, a professor of Genetics, and the program’s co-director with Edward Brodkin, MD, an associate professor of Psychiatry and director of the Adult Autism Spectrum Program at Penn.
“While most genetic studies of ASD have focused on more severely affected individuals with intellectual disability, the efforts of our program will be one of the first large-scale genetic studies to recruit individuals with Asperger syndrome and their family members, including family members with AS, ASD, or without either diagnosis,” Brodkin said. “This approach holds promise for revealing as-yet-undiscovered genetic mechanisms that may be involved in both AS and ASD, as a whole.”
The ASPE team will use model systems to study exactly how mutations in the NRXN1 gene and newly discovered genes affect the biology and function of the brain in individuals with Asperger syndrome. Model systems include fruit flies, mice, and human induced pluripotent stem cells that have been genetically engineered to closely resemble specific human characteristics of ASD. The team will also develop new mouse and fruit fly models to recreate other mutations identified in families in the study.
“Building on our expertise in ASD, with such conditions as Rett syndrome, Fragile X syndrome, and CDKL5 disorder, we plan to significantly improve our understanding of how NRXN1 and other genes affect patients with Asperger syndrome,” said Zhaolan (Joe) Zhou, PhD, an associate professor of Genetics, who along with Tom Jongens, PhD, also an associate professor of Genetics, will lead ASPE’s model system work.
“One of the exciting features of ASPE is that we will be going beyond diagnoses to look at the whole individual, measuring variation in many different aspects of functioning,” said Laura Almasy, PhD, a professor of Genetics who will direct statistical genetic analyses for the project. “This should help us both to identify genes and to understand their role in vulnerability and also in resilience.”
“The overall goal of ASPE is to uncover the full picture of how NRXN1 mutations interact with other gene variants to contribute to Asperger syndrome and other neurodevelopmental conditions,” Rader said. “Guided by these discoveries, the team will explore precise new treatments to improve the lives of individuals affected by Asperger syndrome.”
Casey Browne, PhD, and Golnaz Valhedi, PhD, both from Penn, are also on the program’s faculty.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.